Abstract
We studied the activity of combined oxaliplatin and fluorouracil-leucovorin in 16 consecutive patients with advanced biliary tract adenocarcinomas. The disease control rate (responses and stable disease) was 56% (95% confidence interval, 29-84%) and the median overall survival time was 9.5 months (range 0.9-26.8+). Therefore, this regimen might be active in biliary adenocarcinomas with further evaluation necessary.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
-
Multicenter Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenocarcinoma / drug therapy*
-
Adenocarcinoma / pathology
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Biliary Tract Neoplasms / drug therapy*
-
Biliary Tract Neoplasms / pathology
-
Female
-
Fluorouracil / therapeutic use*
-
Humans
-
Leucovorin / therapeutic use*
-
Male
-
Middle Aged
-
Neoplasm Metastasis
-
Organoplatinum Compounds / therapeutic use*
-
Oxaliplatin
-
Survival Rate
-
Treatment Outcome
Substances
-
Organoplatinum Compounds
-
Oxaliplatin
-
Leucovorin
-
Fluorouracil